At J&J, Oncology Closes In On Immunology As The Leading Pharma Franchise

17 Apr 2018

Global oncology sales grew 45% to $2.31bn in the first quarter, powered by strong growth of Darzalex, Imbruvica and Zytiga, narrowing the gap with J&J's top-selling immunology franchise.

female hand arranging wood block stacking as step stair. Business concept growth success process

At J&J, Oncology Closes In On Immunology As The Leading Pharma Franchise

More from Earnings

More from Business